Cybin Irl Limited

Amorsa Therapeutics, Inc.

Inotek Pharmaceuticals Corporation

Drinksavvy, Inc.

Other

Alternative Innovative Technologies LLC

Arielium Health, LLC

Acadia Pharmaceuticals Inc.

Veroscience LLC

Nivorozhkin, Alex

Alex Nivorozhkin

Anthony H Cincotta

Nelson Landrau

Michael Palfreyman

John Henry Van Duzer

Siya Ram

Michael T Abramson

Garry Southan

John C MacDonald

Brendan Walker

Sergei B Onikienko

Qi Zeng

Andrew L Salzman

Csaba Szabo

Alexander V Zemlyanoi

Clinton E Canal

Joshua A Hartsel

Brett J Greene

Mikhail Viktorovich Shorokhov

Alex Belser

Vladimir Ivanovich Pereguda

Valery Aleksandrovich Chereshnev

The present invention is directed to novel neuro-attenuating norketamine (NANKET) compounds according to any one of formulas (I—shown below), (I-A) and (I-B), or any of the compounds described in Tables A-D, or in any of the Examples provided herein, and pharmaceutically acceptable salts thereof, novel pharmaceutical formulations and novel methods of uses thereof. The present invention also features novel oral neuro-attenuating ketamine (NAKET) and neuro-attenuating norketamine (NANKET) modified-release pharmaceutical formulations, and novel methods of administration thereof, which ensure the steady release of a therapeutically effective amount of ketamine, norketamine, or derivatives thereof from the oral modified-release pharmaceutical formulations without neurologically toxic spikes in plasma concentration of the ketamine, norketamine, or derivatives during the release periods.

Neuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methods

The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with a serotonin 5-HTreceptor.

Deuterated tryptamine derivatives and methods of use

The present invention is directed to methods of producing THC from CBD utilizing non-harsh methodology and resulting in substantially increased yields, as well as devices built upon these novel methods. The methods and devices are material efficient, and in certain embodiments, solvent-free. In particular, in certain embodiments, these methods and related devices are suitable for commercial production of THC from CBD. Furthermore, in certain embodiments, the present invention provides methods of producing THC from CBD in manner that affords tunability to select the ratio of THC-8 to THC-9.

Methods and related tools for CBD conversion to THC

There are disclosed deuterated 2C—X phenethylamine compounds, the use of such compounds in the treatment of diseases associated with a serotonin 5-HTreceptor, pharmaceutical compositions such as tablet compositions and kits containing the compounds, methods of delivering the compounds in a mist via inhalation, and methods of treating diseases or disorders associated with a serotonin 5-HTreceptor, such as central nervous system (CNS) disorders or psychological disorders with the compounds of the invention.

Therapeutic phenethylamine compositions and methods of use

The present invention is directed to novel neuro-attenuating norketamine (NANKET) compounds according to any one of formulas (I&#x2014;shown below), (I-A) and (I-B), or any of the compounds described in Tables A-D, or in any of the Examples provided herein, and pharmaceutically acceptable salts thereof, novel pharmaceutical formulations and novel methods of uses thereof. The present invention also features novel oral neuro-attenuating ketamine (NAKET) and neuro-attenuating norketamine (NANKET) modified-release pharmaceutical formulations, and novel methods of administration thereof, which ensure the steady release of a therapeutically effective amount of ketamine, norketamine, or derivatives thereof from the oral modified-release pharmaceutical formulations without neurologically toxic spikes in plasma concentration of the ketamine, norketamine, or derivatives during the release periods. 

The present invention is directed to oral neuro-attenuating ketamine (NAKET) tablet formulations, and methods of administration, which ensure the steady release of a therapeutically effective concentration of ketamine from an oral tablet without neurologically toxic spikes in ketamine concentration. In particular, the present invention provides single layer oral tablet formulation of NAKET. In a specific embodiment, the NAKET tablet formulation, and methods of administration provide steady administration of NAKET to a subject for 24 hours or greater, for example, up to 36 hours, after a single administration event.

Single-layer oral dose of neuro-attenuating ketamine

Growing community of inventors

West Roxbury, MA, United States of America

Alex Nivorozhkin